Mark J. Levis

26.4k citations
325 papers · 14.6k · 5 hit papers · h-index 64

Impact in

  • Hematology top 0.01%
    • Acute Myeloid Leukemia Research
    • Chronic Myeloid Leukemia Treatments
    • Hematopoietic Stem Cell Transplantation
  • Genetics top 0.05%
    • Chronic Lymphocytic Leukemia Research
    • Myeloproliferative Neoplasms: Diagnosis and Treatment

Papers in

    • Acute Myeloid Leukemia Research 284
    • Chronic Myeloid Leukemia Treatments 170
    • Multiple Myeloma Research and Treatments 29
    • Chronic Lymphocytic Leukemia Research 120
    • Myeloproliferative Neoplasms: Diagnosis and Treatment 42

Mark J. Levis

315 papers receiving 14.4k citations

Mark J. Levis's Hit Papers

The clinical impact of the molecular landscape of acute myeloid leukemia 2023 · 80 citations
800+5+11Years since publication200400600

Peers

Mark J. Levis
Comparison fields: 5 of 106
  • Hematology 10.8k
  • Genetics 3.7k
  • Molecular Biology 6.3k
  • Oncology 1.8k
  • Public Health, Environmental and Occupational Health 1.8k
Replace Hitoshi Kiyoi with:
Hitoshi Kiyoi Japan
Junia V. Melo United Kingdom
B. Douglas Smith United States
Martin Carroll United States
Paresh Vyas United Kingdom
Soheil Meshinchi United States
Jeffrey E. Lancet United States
Daniel A. Pollyea United States
Rod Humerickhouse United States
Robert Schlossman United States
Mark J. Levis relative to Hitoshi Kiyoi Japan Hitoshi Kiyoi's profile →
Citations per field
00.5×2.7×
Hitoshi Kiyoi · 1×
Citations per year

Countries citing papers authored by Mark J. Levis

Since Specialization
Citations

This map shows the geographic impact of Mark J. Levis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark J. Levis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark J. Levis more than expected).

Fields of papers citing papers by Mark J. Levis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark J. Levis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark J. Levis. The network helps show where Mark J. Levis may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark J. Levis, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark J. Levis Line = papers co-authored together Mark J. Levis links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 325 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Targeting FLT3 mutations in AML: review of current knowledge and evidence
Hit paper breakdown →
2019696
2
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Hit paper breakdown →
2012546
3 2004482
4
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
Hit paper breakdown →
2009479
5 2008399
6 2003382
7 2002378
8 2006323
9 2013290
10 2010282
11 2013280
12 1993265
13 2017212
14 2013198
15 2011190
16 1992189
17 2004188
18 2009188
19 2013187
20 2004181

About Mark J. Levis

Mark J. Levis is a scholar working on Hematology, Genetics, Molecular Biology, Public Health, Environmental and Occupational Health and Oncology, having authored 325 papers that have together received 14.6k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (284 papers), Chronic Myeloid Leukemia Treatments (170 papers), Chronic Lymphocytic Leukemia Research (120 papers), Acute Lymphoblastic Leukemia research (44 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (42 papers), Protein Degradation and Inhibitors (33 papers), Multiple Myeloma Research and Treatments (29 papers) and Retinoids in leukemia and cellular processes (22 papers). The work is most often cited by research in Hematology (10.8k citations), Genetics (3.7k citations), Molecular Biology (6.3k citations), Oncology (1.8k citations) and Public Health, Environmental and Occupational Health (1.8k citations). Mark J. Levis has collaborated with scholars based in United States, Germany and Italy. Frequent co-authors include Donald Small, B. Douglas Smith, Naval Daver, Alexander E. Perl, Sabine Käyser, Keith W. Pratz, Nigel H. Russell, Richard F. Schlenk, Jörge E. Cortes and Hagop M. Kantarjian. Their work appears in journals such as Blood, Journal of Clinical Oncology, Blood Advances, Leukemia and Haematologica.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact